Tag: Human Papilloma Virus (HPV)

1. Persistent human papillomavirus-16/18 infection during pregnancy and placental human papillomavirus infection significantly increased the risk of preterm birth compared to infections by other HPV genotypes and separately from a history of cervical dysplasia treatment. 2. The results would support an essential role for community human papillomavirus vaccination programs to...
1. Online training for pediatricians on human papillomavirus (HPV) communication strategies is associated with an increase in rates of HPV vaccination, reducing missed opportunities for HPV vaccination  Evidence Rating Level: 1 (Excellent) Study Rundown: Human papillomavirus (HPV) is one of the most prevalent infectious causes of cancer, linked to more than 33 700 new...
1. No significant increase in spontaneous abortion, preterm birth, major structural defects, or small for gestational age rates were found in women receiving 9vHPV vaccine during pregnancy (within 19 weeks pregnant). 2. No significant differences were found in adverse birth outcomes when comparing vaccinations in women 22 weeks before last...
1. Vaccination against the ten selected pathogens is projected to avert 69 million deaths between 2000 and 2030. 2. Increases in vaccine coverage and introduction of additional vaccines may result in a 72% reduction in lifetime mortality in the 2019 birth cohort.  Evidence Rating Level: 2 (Good) Study Rundown: Vaccines are among...
1. In this national survey, both pediatricians and family physicians (FPs) were more likely to make a strong recommendation for the human papilloma virus (HPV) vaccine in older adolescents as compared to younger adolescents (ages 11 to 12 years). Pediatricians were more likely than FPs to use a presumptive...
Genetically engineered T-cell therapies, such as chimeric antigen receptor T-cells (CAR T-cells), have been approved for the treatment of hematologic malignancies, however, there are limited data to support this approach in the management of epithelial cancers. Human papillomavirus (HPV)-associated epithelial cancers express viral E6 and E7 oncoproteins, which are...
1. A 3-dose regimen of 4-valent human papillomavirus (4vHPV) vaccine administered between the ages of 9-15 years of age was shown to be immunogenic, clinically effective, and without significant adverse effects throughout a 10-year follow-up period.  2. Immunogenic response was most robust when the vaccine was administered during the preadolescent period when...
1. Physicians who used an announcement technique when introducing human papillomavirus (HPV) vaccination had a higher rate of vaccination coverage compared to other techniques. 2. The announcement technique involves stating that vaccinations will be given without inviting questions from patients. Evidence Rating Level: 1 (Excellent)             Study Rundown: Vaccine uptake for the...
1. A greater proportion of teenage girls initiated the human papillomavirus (HPV) vaccine series in states where the tetanus, diphtheria, and pertussis (Tdap) booster and/or the meningococcal vaccine were required for school entry. 2. State laws requiring HPV vaccination but allowing for exemptions for any reason have not been effective...
1. There was a significant decline noted in the prevalence of the human papillomavirus (HPV) types 6, 11, 16, and 18 (those found in the quadrivalent HPV vaccine) among women ages 14 to 24 years between the pre- and post-vaccine time periods. 2. The prevalence of these quadrivalent HPV types (4vHPV)...